NEKTAR THERAPEUTICS (NKTR) Company Report

Nektar Therapeutics announced the closing of its underwritten public offering of approximately $460 million.
The offering included the sale of 7,637,931 shares of common stock at $58.00 per share and 293,103 pre-funded warrants at $57.9999 per pre-funded warrant.
The gross proceeds to Nektar from the offering were approximately $460 million, before deducting underwriting discounts and estimated offering expenses.
The offering included the full exercise by the underwriters of their option to purchase additional shares of common stock.

Feb 13, 2026, 9:15 PM

Press Release

Nektar Therapeutics announces pricing of upsized public offering

NKTR

New Projects/Investments

Nektar Therapeutics announced the pricing of an upsized underwritten public offering on February 11, 2026.
The offering included common stock and pre-funded warrants, with underwriters exercising their option to purchase additional shares in full on February 12, 2026.
The offering is expected to close on February 13, 2026.
Nektar intends to use the net proceeds for general corporate purposes, including research and development, clinical development (Phase 3 trials for rezpegaldesleukin), and manufacturing costs.

Metric	Q4 2025
Shares of Common Stock Sold (shares)	6,603,449
Price per Common Share ($USD)	$58.00
Pre-Funded Warrants Sold (warrants)	293,103
Price per Pre-Funded Warrant ($USD)	$57.9999
Underwriters' Option Shares Exercised (shares)	1,034,482
Gross Proceeds ($USD Millions)	$400
Net Proceeds ($USD Millions)	$432.0

Feb 13, 2026, 1:23 AM

8-K

Nektar Therapeutics Prices Upsized Public Offering

NKTR

New Projects/Investments

Nektar Therapeutics has priced an upsized public offering of common stock and pre-funded warrants, expecting to generate approximately $400 million in gross proceeds.
The offering includes 6,603,449 shares of common stock at $58.00 per share and 293,103 pre-funded warrants at $57.9999 per warrant.
Underwriters have been granted a 30-day option to purchase up to an additional 1,034,482 shares of common stock.
The net proceeds are intended for general corporate purposes, including research and development and clinical development for drug candidates like rezpegaldesleukin.
The offering is anticipated to close on February 13, 2026.

Feb 12, 2026, 3:23 AM

Press Release

Nektar Therapeutics Announces Proposed Public Offering

NKTR

New Projects/Investments

Nektar Therapeutics has commenced an underwritten public offering of $300,000,000 of its common stock and pre-funded warrants.
The company intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of common stock.
Net proceeds from the offering are planned for general corporate purposes, including research and development, clinical development (specifically Phase 3 trials for rezpegaldesleukin), and manufacturing costs.
The proposed offering is subject to market and other conditions, meaning there is no assurance as to its completion, actual size, or terms.

Feb 10, 2026, 9:05 PM

Press Release

Nektar Therapeutics Announces Positive REZOLVE-AD Study Results for Rezpegaldesleukin

NKTR

New Projects/Investments

Guidance Update

Nektar Therapeutics announced positive results from the 36-week blinded maintenance period of its 52-week REZOLVE-AD study for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.
The study demonstrated durable responses at Week 52 with both monthly (Q4W) and quarterly (Q12W) dosing of 24 µg/kg :

Metric	24 µg/kg Q4W (monthly)	24 µg/kg Q12W (quarterly)
EASI-75 Maintained (%)	71%	83%
vIGA-AD 0/1 Maintained (%)	85%	63%

Meaningful improvement in responses was observed, including an up to 5-fold increase in EASI-100 response rates at Week 52 with both dosing regimens.
A favorable safety profile consistent with previous results was observed, with no new safety concerns identified during the 36-week maintenance and escape periods.
The positive results support advancing to a pivotal Phase 3 program, with trials planned to start in Q2 2026 and a BLA filing targeted for 2029.

Feb 10, 2026, 1:05 PM

8-K

Nektar Therapeutics Announces Positive 52-Week Results from Resolve AD Study for Respegaldesleukin

NKTR

Product Launch

New Projects/Investments

Nektar Therapeutics reported positive 52-week results from the Resolve AD study of Respegaldesleukin in moderate to severe atopic dermatitis, demonstrating durability of responses for EASI-75, EASI-90, vIGA, and itch with monthly and quarterly maintenance dosing.
The study showed new and deepening responses with longer-term dosing, including up to a five-fold increase in patients achieving EASI-100 (complete clearance of disease) from week 16 to week 52.
Respegaldesleukin maintained a favorable safety profile over 52 weeks of treatment, consistent with previous data, with low discontinuations for adverse events and no new safety concerns.
The results for ResPEG's longer dosing regimens compared favorably to historically reported long-term maintenance data from other biologics such as Dupilumab and Amlitelimab.
Nektar plans to initiate two global Phase 3 monotherapy trials for Respegaldesleukin in atopic dermatitis in Q2 2026, with a target Biologics License Application (BLA) filing in 2029.

Feb 10, 2026, 1:00 PM

Transcript

Nektar Therapeutics Reports Positive Phase 2b Resolve AD Maintenance Data and Outlines Phase 3 Plans

NKTR

Product Launch

New Projects/Investments

Guidance Update

Nektar Therapeutics announced positive 36-week maintenance data from its Phase 2b Resolve AD study for rezpegaldesleukin, demonstrating excellent durability and deepening of responses, including a five-fold increase in complete disease clearance (EZ100).
The data indicated rezpegaldesleukin's extended dosing regimens (monthly/quarterly) compared favorably to dupilumab and amlitelimab in maintaining key efficacy endpoints, alongside a consistent and favorable safety profile with over 1,000 subjects treated.
The company plans to initiate Phase 3 studies in Q2 2026 for atopic dermatitis, targeting a Biologics License Application (BLA) filing in 2029.
Dermatology experts anticipate rezpegaldesleukin could be a first-line treatment option due to its competitive efficacy, safety, and attractive less frequent dosing regimens.

Feb 10, 2026, 1:00 PM

Transcript

Nektar Therapeutics Announces Positive Phase 2b REZOLVE-AD Topline Results for Rezpegaldesleukin

NKTR

Product Launch

New Projects/Investments

Nektar Therapeutics reported positive topline results from the 36-week maintenance period of its Phase 2b REZOLVE-AD study for Rezpegaldesleukin (Rezpeg) in moderate-to-severe atopic dermatitis.
The study established 24 µg/kg Q2W for 24 weeks as the Phase 3 induction dose, demonstrating rapid onset of action and significant efficacy across key endpoints like EASI-75 and itch relief during the induction phase.
All monthly and quarterly maintenance dosing arms showed durability of responses over 36 weeks, with high percentages of patients maintaining EASI-75 and EASI-90 at Week 52.
The 52-week safety profile was consistent with prior findings, characterized by a low discontinuation rate due to adverse events (3.5%) and no increased risk of serious side effects, with injection site reactions being the most common mild-to-moderate AE.

Feb 10, 2026, 1:00 PM

Presentation

Nektar Therapeutics Announces Positive Phase 2b REZOLVE-AD Study Results for Rezpegaldesleukin

NKTR

New Projects/Investments

Nektar Therapeutics announced positive results from the 52-week REZOLVE-AD study of rezpegaldesleukin for moderate-to-severe atopic dermatitis, demonstrating long-term durability and continued symptom improvement with both monthly and quarterly dosing regimens.
At week 52, 71% and 83% of patients maintained EASI-75 responses with 24 µg/kg monthly and quarterly dosing, respectively, and a 2 to 5-fold increase in EASI-100 response was observed.
The study confirmed a favorable safety profile consistent with previous results, with no new safety concerns identified during the 36-week maintenance period.
These results support the advancement of rezpegaldesleukin to a pivotal Phase 3 program, with the company aiming to submit a Biologics License Application (BLA) in 2029.

Feb 10, 2026, 12:00 PM

Press Release

Nektar Therapeutics to Host Investor Call on REZOLVE-AD Trial Results

NKTR

New Projects/Investments

Nektar Therapeutics (Nasdaq: NKTR) will host an investor call and live webcast on February 10, 2026, at 8:00 am ET / 5:00 am PT, to review topline results from the 36-week maintenance period of its ongoing Phase 2b REZOLVE-AD clinical trial.
The trial is evaluating investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis.
The results will be provided in a morning press release and presented during the webcast.

Feb 9, 2026, 9:15 PM

Press Release